The Brazilian comprehensive response to hepatitis C: from strategic thinking to access to interferon-free therapy.

作者: Fabio Mesquita , Melina Erica Santos , Adele Benzaken , Renato Girade Corrêa , Elisa Cattapan

DOI: 10.1186/S12889-016-3784-4

关键词:

摘要: Hepatitis C affects over 185 million people around the world. This silent disease is responsible for up to 700,000 deaths per year. Despite scientific revolution in diagnosis and treatment, hepatitis control remains a huge challenge due cost of effective medications. In response global outcry epidemic need improve nation’s public health response, Ministry Health Brazil revolutionized treatment by incorporating highly drugs that can be accessed through sustainable universal means. paper describes unique process implementing evidence-informed policy respond update based on estimate prevalence, current international guidelines, cost-effectiveness impact Brazilian Unified System. Through debate an experience report, authors underlie strategic plan implemented according situation analysis emphasized its relatively short-term period. The comprehensive detailed comprising three main objectives: outcomes evaluating new medications at price; elaborate clinical guidelines treat patients; develop awareness campaigns targeted population interest. this scenario, was able obtain unprecedented discount high-medium income country; provided more than 7000 individuals last 2 months 2015; expects 38,000 patients 2016. remarkable applied developed epidemiological data evidence, it motivated engagement country Sustainable Development Goals, which may inspire other developing countries identify ways achieve these goals 2030.

参考文章(9)
D. Lavanchy, Evolving epidemiology of hepatitis C virus Clinical Microbiology and Infection. ,vol. 17, pp. 107- 115 ,(2011) , 10.1111/J.1469-0691.2010.03432.X
Marcelo Naveira, Jarbas Barbosa, Leandro Sereno, Andrea Domanico, Fábio Mesquita, Laura Alves de Souza, 12 years of universal access to hepatitis C treatment: Brazil's comprehensive response. Journal of the International Association of Providers of AIDS Care. ,vol. 13, pp. 560- 567 ,(2014) , 10.1177/2325957414547739
N. Afdhal, G. Everson, J.L. Calleja, G. McCaughan, W.T. Symonds, J. Denning, L. McNair, J.G. McHutchison, S. Arterburn, M. Charlton, R. Reddy, T. Asselah, E. Gane, X. Forns, O68 SOFOSBUVIR AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HCV WITH CIRRHOSIS AND PORTAL HYPERTENSION WITH AND WITHOUT DECOMPENSATION: EARLY VIROLOGIC RESPONSE AND SAFETY Journal of Hepatology. ,vol. 60, ,(2014) , 10.1016/S0168-8278(14)60070-2
Carrie L. Jennings, Kenneth E. Sherman, Hepatitis C and HIV co-infection: new drugs in practice and in the pipeline. Current Hiv\/aids Reports. ,vol. 9, pp. 231- 237 ,(2012) , 10.1007/S11904-012-0122-Z
A. Hill, S. Khoo, J. Fortunak, B. Simmons, N. Ford, Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries Clinical Infectious Diseases. ,vol. 58, pp. 928- 936 ,(2014) , 10.1093/CID/CIU012
Jean-Michel Pawlotsky, Francesco Negro, Alessio Aghemo, Marina Berenguer, Olav Dalgard, Geoffrey Dusheiko, Fiona Marra, Massimo Puoti, Heiner Wedemeyer, EASL Recommendations on Treatment of Hepatitis C 2018 Journal of Hepatology. ,vol. 69, pp. 461- 511 ,(2018) , 10.1016/J.JHEP.2018.03.026
Marcos Amaku, Marcelo Nascimento Burattini, Francisco Antonio Bezerra Coutinho, Luis Fernandez Lopez, Fabio Mesquita, Marcelo Contardo Moscoso Naveira, Gerson Fernando Mendes Pereira, Melina Érica Santos, Eduardo Massad, Estimating the Size of the HCV Infection Prevalence: A Modeling Approach Using the Incidence of Cases Reported to an Official Notification System. Bulletin of Mathematical Biology. ,vol. 78, pp. 970- 990 ,(2016) , 10.1007/S11538-016-0170-4